Financial News

Date Title and Summary Additional Formats
Toggle Summary Rob Fuchs joins ViewRay as Chief Human Resources Officer
CLEVELAND , Nov. 21, 2018 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY), maker of the world's first and only clinical MRI-guided radiation therapy system, announced today the appointment of Robert M. Fuchs as Chief Human Resources Officer effective October 22 , 2018.  Mr.
Toggle Summary ViewRay® to Present at 30th Annual Piper Jaffray Healthcare Conference
CLEVELAND , Nov. 14, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that company management is scheduled to participate in a fireside chat at the 30 th Annual Piper Jaffray Healthcare Conference in New York, NY . Event :       30 th Annual Piper Jaffray Healthcare Conference
Toggle Summary ViewRay Reports Third Quarter 2018 Results
CLEVELAND , Nov. 8, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) ("the Company") today announced financial results for the third quarter ended September 30, 2018 . Third Quarter 2018 Highlights: Total revenue of $17.7 million, primarily from 3 revenue units.
Toggle Summary ViewRay signs agreement with GenesisCare to bring the first MRIdian MRI-guided radiotherapy systems to the UK
New agreement expands access to precision radiotherapy for people with cancer CLEVELAND , Oct. 29, 2018 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced a collaboration with GenesisCare, the largest provider of cancer services in the UK , Spain and Australia , to introduce the first
Toggle Summary Real-Time Adaptive Radiotherapy Capabilities of ViewRay's MRIdian Highlighted at Investor & Analyst Meeting at ASTRO 2018
Leading Oncologists Provide Practical, Clinical, and Economic Rationale for MRIdian MRI-Guided Radiation Therapy in the Treatment of Cancer CLEVELAND , Oct. 22, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced highlights from its investor & analyst meeting during the annual meeting
Toggle Summary ViewRay Announces Conference Call and Webcast of Third Quarter 2018 Financial Results to be Held After Market on November 8, 2018
CLEVELAND , Oct. 18, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its third quarter 2018 financial results, which will take place after the market close on Thursday, November 8, 2018 . ViewRay will hold a conference call on Thursday November
Toggle Summary ASTRO 2018 Presentations to Feature Unique Capabilities and Clinical Outcomes of ViewRay's MRIdian Next Generation Cancer Care
Presentations to Highlight Clinical Value of World's Only FDA-Cleared MRI-guided Radiotherapy System CLEVELAND , Oct. 16, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian® and MRIdian Linac – the world's only FDA -cleared MRI-guided radiation therapy
Toggle Summary ViewRay® to Host Investor & Analyst Meeting at 2018 ASTRO Annual Meeting in San Antonio
Leading Oncologists to Highlight MRIdian MRI-Guided Adaptive Radiotherapy, Discuss Emergence as a New Potential Standard of Cancer Care CLEVELAND , Oct. 9, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will hold a meeting for investors and analysts on Monday,
Toggle Summary ViewRay Appoints Industry Veteran James Alecxih as Chief Commercial Officer
Mr. Alecxih to Lead Company's Commercial Expansion CLEVELAND , Oct. 2, 2018   /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the appointment of James "Jim"
Toggle Summary MRI-Guided Radiation Therapy Aims to Prolong Survival and Reduce Complications for the Most Challenging Cancers
Leading Radiation Oncology Experts Convene to Discuss Future of Radiation Therapy CLEVELAND , Oct. 1, 2018 /PRNewswire/ -- Leading oncology experts from around the world met to discuss the integration of magnetic resonance imaging (MRI) with radiation therapy and its potential to extend life
Toggle Summary ViewRay® to Present at the 2018 Cantor Global Healthcare Conference
CLEVELAND , Sept. 25, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that members of the executive management team are scheduled to present at the Cantor Global Healthcare Conference in New York, NY . Event : 2018 Cantor Global Healthcare Conference Date : Tuesday, October 2,
Toggle Summary ViewRay Announces Equity Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND , Sept. 17, 2018 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced grants of stock options and restricted stock units to several new officers and
Toggle Summary Acibadem Maslak Hospital in Turkey Introduces Next Generation Cancer Care with MRIdian MR-Image Guided Radiation Therapy
Breakthrough Technology Enables High-Definition Soft Tissue Visualization and Real-Time Image Guidance During Beam Delivery CLEVELAND , Sept. 13, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with
Toggle Summary ViewRay® to Participate in Upcoming Conferences
CLEVELAND , Aug. 31, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that members of the executive management team are scheduled to participate in two upcoming investor conferences. The Company will first participate in a fireside chat at the B.
Toggle Summary ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
CLEVELAND , Aug. 17, 2018 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of
Toggle Summary ViewRay Announces Pricing of Public Offering of Common Stock
CLEVELAND , Aug. 14, 2018 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the pricing of an underwritten public offering of 16,216,217 shares of common
Toggle Summary ViewRay Announces Proposed Public Offering of Common Stock
CLEVELAND , Aug. 14, 2018 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced that it has commenced an underwritten public offering of $125.0 million of shares
Toggle Summary ViewRay Reports Second Quarter 2018 Financial Results
CLEVELAND , Aug. 3, 2018 /PRNewswire/ --   ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2018 . Second Quarter 2018 Highlights: Total revenue of $16.4 million, primarily from 3 revenue units, up from $0.7 million in 2Q 2017.
Toggle Summary ViewRay Announces Conference Call and Webcast of Second Quarter 2018 Financial Results to be Held Before Market on August 3, 2018
CLEVELAND , July 31, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2018 financial results, which will take place on Friday, August 3, 2018 before market. ViewRay will hold a conference call on Friday August 3, 2018 at 8:30
Toggle Summary Leading Medical Physics Meeting to Feature More than 50 Presentations on ViewRay's MRIdian MRI-Guided Radiotherapy
Presentations Highlight MRIdian Clinical Experience with On-Table Adaptive Therapy Combined with the Novel Ability to Visualize and Actively Target Tumors that Move CLEVELAND , July 26, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), makers of the world's only FDA -cleared MRI-guided radiation

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

Featured Items

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449
Website: www.amstock.com
Email: info@amstock.com

In Need of Customer Support? Contact

  Language Select